Advances in non-invasive drug delivery for atherosclerotic heart disease

Bibliography

• Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 2014;383(9921):999-1008
   PubMed Web of Science ®Google Scholar
• Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res 2014;114(12):1852-66
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340(2):115-26
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473(7347):317-25
   PubMed Web of Science ®Google Scholar
• Ghattas A, Griffiths HR, Devitt A, et al. Monocytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol 2013;62(17):1541-51
   PubMed Web of Science ®Google Scholar
• Tomey MI, Narula J, Kovacic JC. Advances in the understanding of plaque composition and treatment options: year in review. J Am Coll Cardiol 2014;63(16):1604-16
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-34
   PubMed Web of Science ®Google Scholar
• Michiels C. Endothelial cell functions. J Cell Physiol 2003;196(3):430-43
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Psarros C, Demosthenous M, et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 2014;63(23):2491-502
   PubMed Web of Science ®Google Scholar
• Tsoumani ME, Kalantzi KI, Goudevenos IA, Tselepis AD. Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions. Curr Vasc Pharmacol 2012;10(5):539-49
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012;18(33):5197-214
   PubMed Web of Science ®Google Scholar
• Sakakura K, Nakano M, Otsuka F, et al. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ 2013;22(6):399-411
   PubMed Web of Science ®Google Scholar
• Pollman MJ, Hall JL, Mann MJ, et al. Inhibition of neointimal cell Bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998;4:222-7
   PubMed Web of Science ®Google Scholar
• Wang BY, Ho HKV, Lin PS, et al. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation 1999;99:1236-41
   PubMed Web of Science ®Google Scholar
• Williams H, Johnson JL, Jackson CL, et al. MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis. Cardiovasc Res 2010;87(1):137-46
   PubMed Web of Science ®Google Scholar
• Bombeli T, Schwartz BR, Harlan JM. Endothelial cells undergoing apoptosis become proadhesive for non-activated platelets. Blood 1999;93(11):3831-8
   PubMed Web of Science ®Google Scholar
• Durand E, Scoazec A, Lafont A, et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation 2004;109(21):2503-6
   PubMed Web of Science ®Google Scholar
• Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47:C13-18
   PubMed Web of Science ®Google Scholar
• Gautier EL, Huby T, Witztum JL, et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009;119(13):1795-804
   PubMed Web of Science ®Google Scholar
• Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res 2009;50(Suppl):S382-7
   PubMedGoogle Scholar
• Aikawa E, Nahrendorf M, Figueiredo JL, et al. Osteogenesis asssociates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007;116(24):2841-50
   PubMed Web of Science ®Google Scholar
• Shao JS, Cheng SL, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 2010;55(3):579-92
   PubMed Web of Science ®Google Scholar
• Nadra I, Mason JC, Philippidis P, et al. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase c and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ Res 2005;96:1248-56
   PubMed Web of Science ®Google Scholar
• Nadra I, Boccaccini AR, Philippidis P, et al. Effect of particle size on hydroxyapatite crystal-induced tumor necrosis factor alpha secretion by macrophages. Atherosclerosis 2008;196:98-105
   PubMed Web of Science ®Google Scholar
• Huang H, Virmani R, Younis H, et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 2001;103(8):1051-6
   PubMed Web of Science ®Google Scholar
• Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9
   PubMed Web of Science ®Google Scholar
• Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001;2126-30
   PubMed Web of Science ®Google Scholar
• Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 2004;22:1198
   PubMed Web of Science ®Google Scholar
• Zachary I, Mathur A, Yla-Herttuala S, Martin J. Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2000;20:1512-20
   PubMed Web of Science ®Google Scholar
• Lardizabal JA, Deedwania P. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. Cardiol Clin 2011;29(1):87-103
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-81
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(23 Suppl 1):III39-43
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ (ATT) Collaboration. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60
   PubMed Web of Science ®Google Scholar
• Raju NC, Eikelboom JW. The aspirin controversy in primary prevention. Curr Opin Cardiol 2012;27(5):499-507
   PubMed Web of Science ®Google Scholar
• Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis 2009;207(1):16-23
   PubMed Web of Science ®Google Scholar
• Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371(9626):1761-8
   PubMed Web of Science ®Google Scholar
• Dussault S, Dhahri W, Desjarlais M, et al. Elsibucol inhibits atherosclerosis following arterial injury: multifunctional effects on cholesterol levels, oxidative stress and inflammation. Atherosclerosis 2014;237(1):194-9
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Eikelboom JW, Thompson PL. Colchicine for secondary prevention of cardiovascular disease. Curr Atheroscler Rep 2014;16(3):391
   PubMed Web of Science ®Google Scholar
• Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009;7(Suppl 1):332-9
   PubMed Web of Science ®Google Scholar
• Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep 2013;15(1):295
   PubMed Web of Science ®Google Scholar
• Poupel L, Boissonnas A, Hermand P, et al. Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2013;33:2297-305
   PubMed Web of Science ®Google Scholar
• Fornasa G, Clement M, Groyer E, et al. A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation. Cardiovasc Res 2012;94:30-7
   PubMedGoogle Scholar
• Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005;293:2245-56
   PubMed Web of Science ®Google Scholar
• Tardif JC, L’Allier P L, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010;3:298-307
   PubMed Web of Science ®Google Scholar
• Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-82
   PubMed Web of Science ®Google Scholar
• STABILITY investigators. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702-11
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014;311:252-62
   PubMed Web of Science ®Google Scholar
• Gilbert J, Lekstrom-Himes J, Donaldson D, et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol 2011;107:906-11
   PubMed Web of Science ®Google Scholar
• Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162(4):597-605
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010;148(2):135-46
   PubMed Web of Science ®Google Scholar
• Treuel L, Jiang X, Nienhaus GU. New views on cellular uptake and trafficking of manufactured nanoparticles. J R Soc Interface 2013;10(82):20120939
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7(9):771-82
   PubMed Web of Science ®Google Scholar
• van der Meel R, Fens MH, Vader P, et al. Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release 2014;195C:72-85
   Google Scholar
• Winter PM, Caruthers SD, Zhang H, et al. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging 2008;1(5):624-34
   PubMed Web of Science ®Google Scholar
• Rüegg C, Alghisi GC. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. Recent Results Cancer Res 2010;180:83-101
   PubMedGoogle Scholar
• Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003;108(18):2270-4
   PubMed Web of Science ®Google Scholar
• Saito A, Shimizu H, Doi Y, et al. Immunoliposomal drug-delivery system targeting lectin-like oxidized low-density lipoprotein receptor-1 for carotid plaque lesions in rats. J Neurosurg 2011;115(4):720-7
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 2006;3(10):540-7
   PubMedGoogle Scholar
• De Nardo D, Labzin LI, Kono H, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 2014;15(2):152-60
   PubMed Web of Science ®Google Scholar
• Zhang W, He H, Liu J, et al. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials 2013;34(1):306-19
   PubMed Web of Science ®Google Scholar
• Liu L, He H, Zhang M, et al. Hyaluronic acid-decorated reconstituted high density lipoprotein targeting atherosclerotic lesions. Biomaterials 2014;35(27):8002-14
   PubMed Web of Science ®Google Scholar
• Duivenvoorden R, Tang J, Cormode DP, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 2014;5:3065
   PubMed Web of Science ®Google Scholar
• Katsuki S, Matoba T, Nakashiro S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 2014;129(8):896-906
   PubMed Web of Science ®Google Scholar
• Di Mascolo D, J Lyon C, Aryal S, et al. Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity. J Control Release 2013;170(3):460-8
   PubMed Web of Science ®Google Scholar
• Menon JU, Kona S, Wadajkar AS, et al. Effects of surfactants on the properties of PLGA nanoparticles. J Biomed Mater Res A 2012;100(8):1998-2005
   PubMed Web of Science ®Google Scholar
• Diamond GA, Kaul S. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;357:938-9
   PubMed Web of Science ®Google Scholar
• Nikam N, Steinberg TB, Steinberg DH. Advances in stent technologies and their effect on clinical efficacy and safety. Med Devices (Auckl) 2014;7:165-78
   PubMedGoogle Scholar
• Uwatoku T, Shimokawa H, Abe K, et al. Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circ Res 2003;92(7):e62-9
   PubMed Web of Science ®Google Scholar
• Cohen-Sela E, Rosenzweig O, Gao J, et al. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release 2006;113(1):23-30
   PubMed Web of Science ®Google Scholar
• Banai S, Finkelstein A, Almagor Y, et al. Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial. Am Heart J 2013;165(2):234-40
   PubMed Web of Science ®Google Scholar
• Joner M, Morimoto K, Kasukawa H, et al. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler Thromb Vasc Biol 2008;28(11):1960-6
   PubMed Web of Science ®Google Scholar
• Margolis J, McDonald J, Heuser R, et al. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study. Clin Cardiol 2007;30(4):165-70
   PubMed Web of Science ®Google Scholar
• Chan JM, Rhee JW, Drum CL, et al. In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci USA 2011;108(48):19347-52
   PubMed Web of Science ®Google Scholar
• de la Llera-Moya M, Rothblat GH, Glick JM, England JM. Etoposide treatment suppresses atherosclerotic plaque development in cholesterol-fed rabbits. Arterioscler Thromb 1992;12(11):1363-70
   PubMedGoogle Scholar
• Maranhão RC, Garicochea B, Silva EL, et al. Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia: a possible new strategy for the treatment of the disease. Braz J Med Biol Res 1992;25(10):1003-7
   PubMed Web of Science ®Google Scholar
• Maranhão RC, Cesar TB, Pedroso-Mariani SR, et al. Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids 1993;28(8):691-6
   PubMed Web of Science ®Google Scholar
• Maranhão RC, Garicochea B, Silva EL, et al. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res 1994;54:4660-6
   PubMed Web of Science ®Google Scholar
• Maranhão RC, Tavares ER, Padoveze AF, et al. Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit. Atherosclerosis 2008;197(2):959-66
   PubMed Web of Science ®Google Scholar
• Tavares ER, Freitas FR, Diament J, Maranhão RC. Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions. Int J Nanomedicine 2011;6:2297-304
   PubMed Web of Science ®Google Scholar
• Bulgarelli A, Martins Dias AA, Caramelli B, Maranhão RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol 2012;59(4):308-14
   PubMed Web of Science ®Google Scholar
• Maranhão RC, Graziani SR, Yamaguchi N, et al. Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother Pharmacol 2002;49(6):487-98
   PubMed Web of Science ®Google Scholar
• Valduga CJ, Fernandes DC, Lo Prete AC, et al. Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide. J Pharm Pharmacol 2003;55(12):1615-22
   PubMed Web of Science ®Google Scholar
• Rodrigues DG, Maria DA, Fernandes DC, et al. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother Pharmacol 2005;55(6):565-76
   PubMed Web of Science ®Google Scholar
• Teixeira RS, Valduga CJ, Benvenutti LA, et al. Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. J Pharm Pharmacol 2008;60(10):1287-95
   PubMed Web of Science ®Google Scholar
• Hungria VT, Latrilha MC, Rodrigues DG, et al. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 2004;53(1):51-60
   PubMed Web of Science ®Google Scholar
• Pinheiro KV, Hungria VT, Ficker ES, et al. Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin’s and non-Hodgkin’s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother Pharmacol 2006;57(5):624-30
   PubMed Web of Science ®Google Scholar
• Pires LA, Hegg R, Valduga CJ, et al. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol 2009;63(2):281-7
   PubMed Web of Science ®Google Scholar
• Suzuki J, Isobe M, Morishita R, Nagai R. Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments. Circ J 2010;74:233-9
   PubMed Web of Science ®Google Scholar
• Patel JK, Kittleson M, Kobashigawa JA. Cardiac allograft rejection. Surgeon 2011;9:160-7
   PubMed Web of Science ®Google Scholar
• Lourenço-Filho DD, Maranhão RC, Méndez-Contreras CA, et al. An artificial nanoemulsion carrying paclitaxel decreases the transplant heart vascular disease: a study in a rabbit graft model. J Thorac Cardiovasc Surg 2011;141:1522-8
   PubMed Web of Science ®Google Scholar
• Caruba T, Katsahian S, Schramm C, et al. Treatment for stable coronary artery disease: a network meta-analysis of cost-effectiveness studies. PLoS One 2014;9(6):e98371
   PubMedGoogle Scholar
• Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010;122(10):949-57
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109-22
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363(25):2406-15
   PubMed Web of Science ®Google Scholar